View Older Stories View More Recent Stories
-
Boston Scientific (BSX) PT Raised at Bernstein After 'Another Impressive Beat and Raise'
-
Boston Scientific (BSX) PT Raised to $140 at Mizuho
-
Boston Scientific (BSX) PT Raised to $135 at UBS
-
Boston Scientific (BSX) PT Raised to $124 at Wells Fargo
-
Boston Scientific (BSX) PT Raised to $120 at BofA Securities
-
Boston Scientific (BSX) Tops Q2 EPS by 2c; offers guidance
-
Raymond James Reiterates Strong Buy Rating on Boston Scientific (BSX)
-
TD Cowen on Boston Scientific (BSX): 'We Expect a Strong 2Q'
-
BTIG Reiterates Buy Rating on Boston Scientific (BSX)
-
Medtronic (MDT) gains on RDN NCA proposal
-
TD Cowen Reiterates Buy Rating on Boston Scientific (BSX)
-
Boston Scientific gets FDA approval for expanded atrial fibrillation system
-
These 30 global stocks offer tactical and structural upside, says RBC
-
Boston Scientific (BSX) to benefit from Olympus import warning - BofA Securities
-
Leerink starts coverage on Boston Scientific and Medtronic with bullish ratings
-
Leerink Partners Starts Boston Scientific (BSX) at Outperform
-
Bernstein on Boston Scientific (BSX): 'We See a Strong Setup for the Stock and Continued Upside'
-
Piper Sandler on Boston Scientific (BSX): 'Plenty of Growth Drivers Lined Up Next'
-
TD Cowen on Boston Scientific (BSX): 'we do not anticipate any major changes to consensus estimates for BSX in the near term'
-
Evercore ISI on Boston Scientific (BSX) Read-through: 'This should be a positive for ABT & MDT'
-
JPMorgan on Boston Scientific (BSX): 'We’d be buyers of BSX on any material weakness'
-
Citi Reiterates 'Top Pick' on Boston Scientific (BSX)
-
Needham on Boston Scientific (BSX): 'any weakness in BSX shares today as a buying opportunity'
-
Edwards Lifesciences (EW) gains after Boston Scientific (BSX) ends worldwide sales of the ACURATE neo2 and ACURATE Prime
-
Boston Scientific (BSX) is discontinuing worldwide sales of the ACURATE neo2 and ACURATE Prime
-
Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick
-
These 2 sectors are under-owned, Barclays says and advises where to invest
-
Erste Group Starts Boston Scientific (BSX) at Buy, 'We expect the positive business development to continue in the longer term'
-
Boston Scientific (BSX) reports Second phase of ADVANTAGE AF study of FARAPULSE Pulsed Field Ablation System meets primary safety and efficacy endpoints
-
Boston Scientific (BSX) PT Raised at RBC Capital Following 'Encouraging Guidance Raise'
-
Canaccord Genuity Reiterates Buy Rating on Boston Scientific (BSX)
-
Boston Scientific shares rise on strong Q1 results, raised EPS guidance
-
Boston Scientific (BSX) Announces CFO Retirement
-
Boston Scientific (BSX) Tops Q1 EPS by 8c, Beats on Revenue; Offers FY25 EPS Guidance
-
TD Cowen: 'Boston Scientific (BSX) Remains a Best Idea'
-
Needham Upgrades Boston Scientific (BSX) to Buy
-
RBC Capital on Boston Scientific (BSX): 'We See Room for a Beat and Raise'
-
RBC Capital Assesses U.S. Tariff Impact Across Industries
-
RBC Capital on Boston Scientific (BSX): 'Strong Near-Term Trends With Visibility On Growth Durability'
-
RBC Capital: 'Opportunities Across MedTech Stocks'
-
Jefferies Reiterates Hold Rating on Edwards Lifesciences (EW)
-
Boston Scientific (BSX) announces agreement to acquire SoniVie Ltd.
-
Boston Scientific announces board member Charles Dockendorff's departure
-
Boston Scientific (BSX) PT Raised to $120 at Stifel
-
Raymond James is very bullish on this MedTech stock. Here's why
-
Boston Scientific (BSX) PT Raised to $116 at RBC; 'Solid PFA & Broad Portfolio Momentum Offer Room for 2025 Upside'
-
Boston Scientific (BSX) PT Raised to $120 at Truist; 'We Think '25 Guide Has Room for Upside'
-
Boston Scientific (BSX) PT Raised to $130 at Mizuho
-
Boston Scientific (BSX) PT Raised to $117 at Canaccord Genuity
-
Needham Reiterates Hold Rating on Boston Scientific (BSX)
